Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
or

Apellis Pharmaceuticals Inc (APLS)

Apellis Pharmaceuticals Inc (APLS)
26.00 -0.33 (-1.25%) 02/27/25 [NASDAQ]
26.00 x 100 27.30 x 100
Realtime by (Cboe BZX)
26.00 x 100 27.30 x 100
Realtime 26.00 unch (unch) 17:14 ET
Quote Overview for Thu, Feb 27th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
26.00
Day High
27.54
Open 26.58
Previous Close 26.33 26.33
Volume 2,500,300 2,500,300
Avg Vol 1,502,115 1,502,115
Stochastic %K 8.25% 8.25%
Weighted Alpha -56.90 -56.90
5-Day Change -2.35 (-8.29%) -2.35 (-8.29%)
52-Week Range 24.34 - 70.45 24.34 - 70.45
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,275,268
  • Shares Outstanding, K 124,393
  • Annual Sales, $ 396,590 K
  • Annual Income, $ -528,630 K
  • EBIT $ -223 M
  • EBITDA $ -195 M
  • 60-Month Beta 0.96
  • Price/Sales 4.53
  • Price/Cash Flow N/A
  • Price/Book 14.11

Options Overview Details

View History
  • Implied Volatility 77.40% ( +11.73%)
  • Historical Volatility 36.59%
  • IV Percentile 78%
  • IV Rank 63.97%
  • IV High 92.86% on 07/18/24
  • IV Low 49.96% on 01/23/25
  • Put/Call Vol Ratio 2.84
  • Today's Volume 3,283
  • Volume Avg (30-Day) 582
  • Put/Call OI Ratio 0.70
  • Today's Open Interest 30,472
  • Open Int (30-Day) 31,407

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 22 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.39
  • Number of Estimates 13
  • High Estimate -0.26
  • Low Estimate -0.57
  • Prior Year -0.73
  • Growth Rate Est. (year over year) +46.58%

Price Performance

See More
Period Period Low Period High Performance
1-Month
26.00 unch
on 02/27/25
Period Open: 29.79
30.60 -15.03%
on 02/05/25
-3.79 (-12.72%)
since 01/27/25
3-Month
26.00 unch
on 02/27/25
Period Open: 34.14
35.72 -27.21%
on 12/09/24
-8.14 (-23.84%)
since 11/27/24
52-Week
24.34 +6.82%
on 11/05/24
Period Open: 69.35
70.45 -63.09%
on 02/28/24
-43.35 (-62.51%)
since 02/27/24

Most Recent Stories

More News
Apellis Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference

APLS : 26.00 (-1.25%)
Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGN

APLS : 26.00 (-1.25%)
Apellis Pharmaceuticals to Host Conference Call on February 28, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results

APLS : 26.00 (-1.25%)
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

APLS : 26.00 (-1.25%)
Apellis Receives Approval of SYFOVRE® (pegcetacoplan) in Australia for Geographic Atrophy (GA)

APLS : 26.00 (-1.25%)
Apellis Highlights Commercial Growth and Strategic Priorities at 43rd Annual J.P. Morgan Healthcare Conference

APLS : 26.00 (-1.25%)
Apellis Announces Keli Walbert to Join the Board of Directors

APLS : 26.00 (-1.25%)
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

APLS : 26.00 (-1.25%)
Apellis Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

APLS : 26.00 (-1.25%)
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

APLS : 26.00 (-1.25%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Apellis Pharmaceuticals, Inc. is a clinical-stage biotech focused on the development of novel therapeutics, which work through the inhibition of the complement system, specially targeting the C3 protein of the complement system to treat autoimmune and inflammatory diseases.

See More

Key Turning Points

3rd Resistance Point 28.57
2nd Resistance Point 28.05
1st Resistance Point 27.03
Last Price 26.00
1st Support Level 25.49
2nd Support Level 24.97
3rd Support Level 23.95

See More

52-Week High 70.45
Fibonacci 61.8% 52.84
Fibonacci 50% 47.39
Fibonacci 38.2% 41.95
Last Price 26.00
52-Week Low 24.34

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

Mastering Fibonacci: The Hidden Order in Market Movements